Abstract Background: PM RMS represents a diagnostic and therapeutic problem as it is less visible than other superficial head and neck sites, and has tendency to local and intracranial extension. Objectives: The aim of this work is to study the treatment outcome, overall survival (OS) and event free survival (EFS) of pediatric PM RMS patients diagnosed and treated at the Children Cancer Hospital-Egypt [CCHE-57357] during a 4 year period. Methods: Retrospective review of charts of newly diagnosed pediatric PM RMS patients diagnosed and treated in CCHE during the period between July 2007 and the end of June 2011. Results: Forty-two pediatric patients with PM RMS with age ranging from 3 months to 17.7 years (median 6.9 years) were studied. The follow up period ranged from 4 to 55 months with a median of 24.8 months. 
Introduction
Rhabdomyosarcoma (RMS) -originating from the primitive mesenchymal tissue -is the commonest pediatric soft-tissue sarcoma, constituting 3-5% of childhood malignancies [1] . The head and neck region represents about 35% of RMS [1] . Parameningeal rhabdomyosarcomas (PM RMS) are tumors arising from sites adjacent to the meninges (nasopharynx, middle ear, paranasal sinuses, infratemporal and pterygopalatine fossa) and constitute half of all head and neck RMS cases [2] [3] [4] . PM RMS represents a diagnostic and therapeutic problem as it is less visible than superficial head and neck sites, and has a tendency of invasion of critical anatomic structures.
The outcome of PM RMS is still unsatisfactory compared to other sites, necessitating a more aggressive therapy [6] [7] [8] , mostly due to delay in diagnosis [1] , tumor tendency to intracranial spread [5] and increased local recurrence [5] [6] [7] [8] [9] [10] .
The current standard treatment for RMS consists of a multimodal therapy involving chemotherapy, radiotherapy and surgery [11] . On the surgical level, PM RMS represents an obstacle. Radical surgical approach is not feasible because of the vital structures involved, and the likelihood for major cosmetic consequences [12] .
Radiotherapy -known to play an important part -is needed for satisfactory local control, and has especially benefited from the new imaging tools, which enable a better target field design [13] .
The aim of this work is to study the treatment outcome, overall survival (OS) and event free survival (EFS) of pediatric PM RMS patients diagnosed and treated at the Children Cancer Hospital-Egypt [CCHE-57357] during a 4 year period (2007) (2008) (2009) (2010) (2011) .
Patients and methods
A retrospective review of charts of newly diagnosed pediatric PM RMS patients diagnosed and treated in CCHE during the period between July 2007 and the end of June 2011. All patients were followed up till the end of March 2012.
Patients were included in the study if they fulfilled the following criteria: (a) previously untreated, (b) below 18 years, (c) confirmed tissue biopsy in the parameningeal site and (d) signed an informed consent.
Pretreatment investigations
A-Complete physical examination including: Weight, height and surface area, site and clinical extent of the primary tumor and regional lymph node enlargement. Histological categorization was based on pediatric international classification of rhabdomyosarcoma.
Definition of parameningeal sites
1. Middle ear: Medial to or extends through the tympanic membrane and appears to be arising in the ear canal. 2. Nasal cavity and paranasal sinuses: maxillary, ethmoid, and sphenoid sinus. 3. Nasopharynx: Bounded anteriorly by the back of the nasal septum, superiorly by the sphenoid sinus, inferiorly by a level corresponding to the soft palate, and laterally and posteriorly by the pharyngeal walls. 4. Infratemporal fossa/pterygopalatine and parapharyngeal area: Tissues bounded laterally by the medial lobe of the parotid gland and medially by the pharynx that may extend through the parotid gland and present as a mass in the cheek. The superior boundary of this tissue volume is the base of the skull just under the temporal lobe, hence the term ''infratemporal''.
Pretreatment staging
Patients were assigned according to the clinical TNM pretreatment staging system based on site, size, clinical regional nodal status and distant spread, using preoperative imaging and physical findings: 
Chemotherapy
It was given according to the IRS IVth study 28 ( Fig. 1) .
It consisted of alternating doses of multi-agent chemotherapy VAC every 21 days with weekly vincristine. Doses of chemotherapy were: -Vincristine (VCR); 1.5 mg/m 2 IV push. -Actinomycin (DACT); 1.35 mg/m 2 IV push.
-Cyclophosphamide (CTX); 1.5 mg/m 2 at weeks 0 and 3 to be increased to 1.8 gm/m 2 if tolerated, given IV infusion over 2 h with MESNA and IV fluids.
Radiotherapy
Patients with parameningeal tumors who had erosion of the base of the skull and/or cranial nerve palsy without evidence Figure 1 Chemotherapy protocol.
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of intracranial extension received radiotherapy to both the primary and metastatic sites at week 12. If patients had evidence of intracranial extension and/or cranial nerve palsy, radiation therapy was started at week 1 (Day 0).
Target volume definitions
CT-based planning techniques were used. All treatment planning was based upon the following target definitions. Treatment was prescribed to the PTV, which was derived from the GTV and CTV as follows: Gross tumor volume (GTV): The volume occupied at diagnosis by a visible or palpable disease.
Clinical target volume (CTV): The GTV plus any sites that warrant irradiation because of potential occult tumor involvement.
The PTV is generated by adding a margin to the CTV in order to compensate for variability in treatment setup, breathing, or motion during treatment. This margin is 5 mm as per department protocol for the head and neck.
All patients received radiotherapy to the primary and metastatic sites, with a total dose of 50.4 Gy in 28 fractions of 1.8 Gy delivered once a day, 5 days a week for all sites.
Treatment technique
Volume-based (three-dimensional) planning was applied leading to a homogenous dose to PTV with a minimal dose to the surrounding organs at risk, not exceeding the tolerance level of any of them. Intensity modulated radiation therapy (IMRT) was performed in most of the patients.
Evaluation criteria
Complete response (CR): Complete disappearance of the tumor confirmed at >4 weeks.
Partial response (PR): At least 64% decrease in volume compared to the baseline.
Progressive disease (PD): At least 40% increase in tumor volume compared to the smallest measurement obtained since the beginning of the therapy.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest disease measurement since the treatment started.
Relapse/recurrence(R): appearance of new lesions or reappearance of old lesions for patients in CR. 
Statistical analysis
Event-free survival (EFS) and overall survival (OS) were estimated according to the Kaplan-Meier method. To study EFS, patients were evaluated from the date of diagnosis to the date of disease progression, recurrence, or death due to any cause. For OS, patients were evaluated from diagnosis to death. The time scale extended as far as the most recent follow up if none of these endpoints were reached. To establish the potential value of prognostic factors, survival curves for different subgroups of patients were compared using the log rank test.
Results
Out of 148 new RMS patients presented during the study period (2007-2011), 42 had PM RMS representing 28.3% of the whole RMS patients.
The age of the patients ranged from 3 months to 17.7 years (median 6.9). They were 25 males and 17 females with a male to female ratio of 1.3:1. Follow up period ranged from 4 to 55 months with a median of 24.8 months. The most common tumor site was nasopharyngeal, followed by maxillary and parapharyngeal mass. The most common metastatic site was the lungs (7/11-63.6%), followed by bone (2/11-18.2%) and multiple sites [bone + bone marrow + lung] in (2/11-18.2%). Table 3 shows the initial site and TNM staging of the 42 studied patients.
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Event free survival (EFS) was 48 ± 8.6% for the whole group at the same period (Fig. 4) . The non-metastatic patients had a higher 3-year EFS than metastatic ones [56.5 ± 9.7% versus 24.9 ± 14.9%]. However, this difference did not reach to the level of statistical significance (p = 0. 127) (Fig. 5) .
Discussion
PM RMS outcome remains a real problem with much inferior results than other sites. The aim of our work is to study the epidemiologic data, treatment outcome, OS and EFS of newly diagnosed, pediatric PM RMS patients treated at the Children's Cancer Hospital Egypt 57357 (CCHE) during a 4 year period.
Age of our patients at presentation ranged from 3 months to 17.7 years (mean 9.1, median 6.9 ± 4.3 years). Our results are in concordance with many other authors, who reported a median age of 7.7 years (range 0.3-19.9) [14] . Most of the patients (67-87%) were below 14 years [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Similarly, Douglas et al. reported a median age of 8.5 years (range 1.5-19 years) [15] [16] . This appears coherent in RMS, a disease being considered the most common soft tissue sarcoma of early childhood [17] . Moreover, we have noticed a slight male predominance, as our M:F ratio was 1.3: 1. This male predominance was confirmed by Douglas et al., who detected a male to female ratio of 1.6:1 [16] . Other authors also notified that 58-63% of their patients were males [3, 14, 18] .
In our study, site was not easy to establish because more than one of the parameningeal sites were involved, and most of the patients presented with a locally advanced tumor. The most common tumor site detected was nasopharyngeal followed by maxillary and parapharyngeal masses. Similar results were shown by many other authors, as their main tumor site in nasopharynx followed by parapharyngeal and maxillary sinus [16] . Contrarily, Cristina et al. showed the most frequent tumor site is the paranasal sinuses, followed by pterygopalatine and infratemporal fossa [19] .
Half of our patients presented in stage III while 23.8% of patients had stage II and 26.2% had stage IV. These figures were in concordance with what is described by other authors as PM RMS which is mainly a stage III followed by stage IV disease. Such advanced tumor stage may be explained by being less visible than the superficial head and neck sites [20] , and the tendency to leptomeningeal progression [5] .
The embryonal pathological subtype predominated in our patients (73.8%). Similar results were also reported in the literature representing 50-70% of patients [3, 19, 21, 22] .
PM RMS treatment has undergone breakthrough changes since the start of the International Rhabdomyosarcoma Study Group trials [IRSG] 40 years ago [23, 24] . The IRS-IV pilot study [25] showed the VAC therapy (Vincristine, Actinomycin D and Cyclophosphamide) is as equally effective as other chemotherapeutic regimens as VAI (Vincristine, Actinomycin D, Ifosfamide) or VEI (Vincristine, Ifosfamide, Etoposide).
In the present study, 62% of our patients achieved CR and remained in continuous complete remission (CCR) by the end of the study period, while the rest (38%) had no response or progressed on 1st line regimen. Of 424 PM-RMS patients enrolled on IRSG protocols from 1984 to 1995, 84% achieved response including all tumor sites. Local failure was the most common site for unresected non metastatic RMS in IRS III and IV (15-17%) [26] [27] [28] [29] . In a study conducted by Smith et al. assessing intensive chemotherapeutic regimen with delayed local radiotherapy at week 21, 38% of their patients achieved complete response while 62% had partial response [30] . In another study including 26 pediatric patients of group III PM-RMS, the radiographic response following neo-adjuvant chemotherapy till week 12 was CR in 22% and PR in 74%. The authors concluded that radiotherapy could be delayed to allow for better local regional control [16] . Similar regimen was also applied in another study to 14 PM-RMS patients; nobody showed progression during induction [16, 31] .
In our series disease progression was the cause of death in 26.1%, while 7.1% of our patients died due to septicemia following salvage chemotherapy. All the patients were stages III or IV disease.
The present study results are worse than those reported in similar studies. Out of 13 patients included in Smith et al. study, 2 patients (15.3%) died from recurrent disease [30] . In another study including 26 patients, four failures were detected, all were relapsing evenly either as a local disease or distant metastasis, in addition to one patient who died from 2ry leukemia (19.2%) [16] .
At 36 months, OS in our group is 58.4% and that of EFS is 48%. These figures are again worse than those reported by Maurer et al. as their overall survival was 69% [3] . In another study, the OS was similar to that in the present study (60% at 5 years), but included all the sites of head and neck with multi modality treatment [21] . Both tumor size and age of patients were found to influence survival [21] . The prognosis of parameningeal RMS was the worst in a study where the OS was even less to 27% at 5 years if no complete remission on chemotherapy is reached [21] . Similar figures were obtained for the OS at 5 and 10 years, and were 20.4% [18] . Maurer et al. reported 5 years OS of 92% for orbital tumors, compared to 81% for nonparameningeal tumors and 69% in PM sites [3] .
Conclusion
PM RMS remains a diagnostic and therapeutic problem. Tumor stage, size, and distant metastasis and response to chemotherapy remain the most important prognostic factors. Multimodality chemotherapy is the main line of treatment, but with a smaller role to surgery due to early intracranial extension, and INVASION OF VITAL ORGANS. Late presentation and advanced local disease compromise treatment options and decrease OS and EFS of our patients.
